Vanda Q1 net loss widens to $29.5M; Fanapt sales up 14% but PONVORY down 18%

Vanda Pharmaceuticals Inc.

2025-Q1 EPS reported -$0.50 revenue$50,041,000

Net product sales $50.0M (+5% YoY); net loss $29.5M vs $4.1M loss a year ago.
Diluted EPS -$0.50; loss reflects $15M imsidolimab license fee and higher commercial spend.
Fanapt sales $23.5M (+14%), HETLIOZ $20.9M (+4%), PONVORY $5.6M (-18%).
Cash $340.9M; full-year guidance: revenues $210-250M, year-end cash $280-320M.
Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA PDUFA Feb 21, 2026; imsidolimab BLA expected 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.